|
1
|
Coffelt SB, Kersten K, Doornebal CW,
Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M,
Hawinkels LJAC, Jonkers J and de Visser KE: IL-17-producing γδ T
cells and neutrophils conspire to promote breast cancer metastasis.
Nature. 522:345–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jia Y, Xu L, Lin Q, Zhu M, Ding L, Wu K
and Lu Y: Levels of lymphocyte subsets in peripheral blood prior
treatment are associated with aggressive breast cancer phenotypes
or subtypes. Med Oncol. 31:9812014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan
GH, See MH, Jamaris S and Taib NA: Utility of pre-treatment
neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as
prognostic factors in breast cancer. Br J Cancer. 113:150–158.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu L, Mayes PA, Eastman S, Shi H,
Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson
C, et al: The BRAF and MEK inhibitors dabrafenib and trametinib:
Effects on immune function and in combination with immunomodulatory
antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res.
21:1639–1651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Minckwitz G, Eidtmann H, Rezai M,
Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C,
Kreienberg R, et al: Neoadjuvant chemotherapy and bevacizumab for
HER2-negative breast cancer. N Engl J Med. 366:299–309. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan W, Zhang W, Strasner A, Grivennikov S,
Cheng JQ, Hoffman RM and Karin M: Tumour-infiltrating regulatory T
cells stimulate mammary cancer metastasis through RANKL-RANK
signalling. Nature. 470:548–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Denkert C, von Minckwitz G, Brase JC, Sinn
BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD,
et al: Tumor-infiltrating lymphocytes and response to neoadjuvant
chemotherapy with or without carboplatin in human epidermal growth
factor receptor 2-positive and triple-negative primary breast
cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ruffell B, Au A, Rugo HS, Esserman LJ,
Hwang ES and Coussens LM: Leukocyte composition of human breast
cancer. Proc Natl Acad Sci USA. 109:2796–2801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH,
Lee HE, Kim YJ, Kim JH and Park SY: Tumour-infiltrating CD8+
lymphocytes as an independent predictive factor for pathological
complete response to primary systemic therapy in breast cancer. Br
J Cancer. 109:2705–2713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coffer PJ and Burgering BM: Forkhead-box
transcription factors and their role in the immune system. Nat Rev
Immunol. 4:889–899. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winerdal ME, Marits P, Winerdal M, Hasan
M, Rosenblatt R, Tolf A, Selling K, Sherif A and Winqvist O: FOXP3
and survival in urinary bladder cancer. BJU Int. 108:1672–1678.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jensen HK, Donskov F, Nordsmark M,
Marcussen N and von der Maase H: Increased intratumoral
FOXP3-positive regulatory immune cells during interleukin-2
treatment in metastatic renal cell carcinoma. Clin Cancer Res.
15:1052–1058. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang MJ, Kim KM, Bae JS, Park HS, Lee H,
Chung MJ, Moon WS, Lee DG and Jang KY: Tumor-infiltrating
PD1-positive lymphocytes and FoxP3-positive regulatory T cells
predict distant metastatic relapse and survival of clear cell renal
cell carcinoma. Transl Oncol. 6:282–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matkowski R, Gisterek I, Halon A, Lacko A,
Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J,
Zolnierek A and Kornafel J: The prognostic role of
tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer.
Anticancer Res. 29:2445–2451. 2009.PubMed/NCBI
|
|
18
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ladoire S, Arnould L, Mignot G, Coudert B,
Rébé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, et
al: Presence of Foxp3 expression in tumor cells predicts better
survival in HER2-overexpressing breast cancer patients treated with
neoadjuvant chemotherapy. Breast Cancer Res Treat. 125:65–72. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members, : Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen International expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Demaria S, Pikarsky E, Karin M, Coussens
LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo
E, et al: Cancer and inflammation: promise for biologic therapy. J
Immunother. 33:335–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tung NM and Winer EP: Tumor-infiltrating
lymphocytes and response to platinum in triple-negative breast
cancer. J Clin Oncol. 33:969–971. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohammed ZM, Going JJ, Edwards J,
Elsberger B, Doughty JC and McMillan DC: The relationship between
components of tumour inflammatory cell infiltrate and
clinicopathological factors and survival in patients with primary
operable invasive ductal breast cancer. Br J Cancer. 107:864–873.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Walser TC, Ma X, Kundu N, Dorsey R,
Goloubeva O and Fulton AM: Immune-mediated modulation of breast
cancer growth and metastasis by the chemokine Mig (CXCL9) in a
murine model. J Immunother. 30:490–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohtani H, Jin Z, Takegawa S, Nakayama T
and Yoshie O: Abundant expression of CXCL9 (MIG) by stromal cells
that include dendritic cells and accumulation of CXCR3+ T cells in
lymphocyte-rich gastric carcinoma. J Pathol. 217:21–31. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong DD, Yie SM, Li K, Li F, Xu Y, Xu G,
Song L and Yang H: Importance of HLA-G expression and tumor
infiltrating lymphocytes in molecular subtypes of breast cancer.
Hum Immunol. 73:998–1004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martinet L, Garrido I, Filleron T, Le
Guellec S, Bellard E, Fournie JJ, Rochaix P and Girard JP: Human
solid tumors contain high endothelial venules: Association with T-
and B-lymphocyte infiltration and favorable prognosis in breast
cancer. Cancer Res. 71:5678–5687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacquemier J, Bertucci F, Finetti P,
Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, van den
Eynde B, Birnbaum D, Olive D and Xerri L: High expression of
indoleamine 2,3-dioxygenase in the tumour is associated with
medullary features and favourable outcome in basal-like breast
carcinoma. Int J Cancer. 130:96–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oda N, Shimazu K, Naoi Y, Morimoto K,
Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ and Noguchi S:
Intratumoral regulatory T cells as an independent predictive factor
for pathological complete response to neoadjuvant paclitaxel
followed by 5-FU/epirubicin/cyclophosphamide in breast cancer
patients. Breast Cancer Res Treat. 136:107–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee HJ, Seo JY, Ahn JH, Ahn SH and Gong G:
Tumor-associated lymphocytes predict response to neoadjuvant
chemotherapy in breast cancer patients. J Breast Cancer. 16:32–39.
2013. View Article : Google Scholar : PubMed/NCBI
|
